252050 Fostering MCH and chronic disease collaboration: Lessons from the Gestational Diabetes Collaborative

Monday, October 31, 2011: 2:30 PM

Joan Ware, BSN, MSPH , National Association of Chronic Disease Directors, Salt Lake City, UT
Gestational diabetes (GDM) affects 2-10% of pregnancies in the US. Up to one-third of affected women will have impaired glucose metabolism at postpartum screening, and an estimated 15-50% will develop diabetes in the decades following the affected pregnancies.

With more emphasis on the importance of chronic disease prevention and reduction of risk factors in women of child bearing age, especially related to diabetes, obesity, hypertension, and tobacco use, collaboration of chronic disease and maternal and child health (MCH) programs has become a vital issue. Seven states have established collaborative teams to address GDM improvement of data collection, documentation of care, increasing postpartum glucose testing, and provision of long-term follow-up. These collaborations have the potential for more efficient use of staff, funds, surveillance and intervention efforts. This presentation describes barriers, enablers, strategies, and outcomes as experienced by the collaborating states.

Learning Areas:
Program planning

Learning Objectives:
Describe the rationale for MCH and chronic disease collaboration to prevent type 2 diabetes and other chronic diseases in women of child bearing age Describe at least two important GDM issues Describe possible evidence-based practices public health could implement to address GDM

Presenting author's disclosure statement:

Qualified on the content I am responsible for because: I am qualified to present because I have over 30 years in developing, implementing and evaluating chronic disease prevention programs, and 5 years working with multiple state MCH and Chronic Disease collaborations.
Any relevant financial relationships? No

I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.